MetaboType AnalyticsMetaboTypeANALYTICS
Back to home
For Pharma & Biotech

Better biological resolution for autoimmune drug development.

A clinical diagnosis can contain multiple underlying biological phenotypes. MetaboType is building longitudinal metabolic biomarkers to help drug developers characterize that heterogeneity and measure treatment response.

A clinical trial patient in conversation with a researcher, understanding treatment response

What is available — and what is in development

Not every application is at the same stage. This is how we think about the maturity of MetaboType for drug development.

Available now / near-term collaboration

Exploratory metabolomic profilingLongitudinal patient phenotypingPharmacodynamic analysisRetrospective biobank studiesDecentralized urine samplingIntegration of metabolomics with trial outcomes

In development

Treatment-response signaturesResponder / non-responder classificationPatient-stratification modelsLupus nephritis biomarker signaturesFlare-related biomarkers

Longer-term validated applications

Predictive response modelsPatient-enrichment biomarkersValidated nephritis endpointsValidated flare-risk modelsClinically deployable decision-support tools

From baseline to clinical outcome

The same longitudinal architecture supports pharmaceutical programs — connecting early biological change to eventual clinical outcomes.

Baseline
Therapy
Biological Response
Clinical Outcome

Each stage can be addressed at the maturity level appropriate to your program — available now, in development, or as a future validated application.

What a partner receives

Examples of collaboration deliverables, scoped to the program.

  • Curated metabolomic datasets
  • Statistical and biological analysis
  • Candidate biomarker signatures
  • Longitudinal trajectory analysis
  • Pharmacodynamic response analysis
  • Integration with clinical outcomes
  • Co-developed biomarker strategy
  • Study-design input for future validation
A researcher analyzing longitudinal metabolomic data on analytical instrumentation

Explore a biomarker collaboration

We are seeking collaborations with pharma and biotech developing therapies for lupus and related autoimmune diseases.

Discuss a Collaboration